Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 3 9639 6036
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees81
Next Earnings DateN/A
OptionableNot Optionable
Mesoblast (OTCMKTS:MEOBF) Frequently Asked Questions
What is Mesoblast's stock symbol?
Mesoblast trades on the OTCMKTS under the ticker symbol "MEOBF."
Has Mesoblast been receiving favorable news coverage?
Headlines about MEOBF stock have been trending positive on Friday, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Mesoblast earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Mesoblast.
Who are some of Mesoblast's key competitors?
Some companies that are related to Mesoblast include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), Apotheca Biosciences (CBDC), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Baudax Bio (BXRXV), BerGenBio ASA (BRRGF), Biocure Technology (CURE), Canada House Wellness Group (CHV), Cannabics Pharmaceuticals (CNBX), CannaRoyalty (ORHOF), Cardiome Pharma (COM) and China Longyi Group Int'l (CGYG).
What other stocks do shareholders of Mesoblast own?
Who are Mesoblast's key executives?
Mesoblast's management team includes the folowing people:
- Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)
- Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)
- Mr. Roger D. Brown BA, Head of Spinal Orthopedic Disorders
- Mr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)
- Dr. Kenneth M. Borow M.D., Exec. (Age 71)
How do I buy shares of Mesoblast?
Shares of MEOBF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Mesoblast's stock price today?
One share of MEOBF stock can currently be purchased for approximately $1.40.
What is Mesoblast's official website?
How can I contact Mesoblast?
The company can be reached via phone at 61 3 9639 6036.
MarketBeat Community Rating for Mesoblast (OTCMKTS MEOBF)
MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MEOBF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEOBF will underperform the S&P 500 over the long term. You may vote once every thirty days.
